The current treatment strategy for gouty arthritis
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA). Febuxostat is a more potent inhibitor of XOR than allopurinol, as confirmed by that target UA levels have been achieved more freque...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/844 |
| id |
doaj-9cecfccf58594330a48de2115cc2febd |
|---|---|
| record_format |
Article |
| spelling |
doaj-9cecfccf58594330a48de2115cc2febd2021-07-29T09:00:12ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2018-09-01123707510.14412/1996-7012-2018-3-70-752109The current treatment strategy for gouty arthritisM. S. Petrova0М. M. Musiychuk1V. I. Mazurov2I.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaFebuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA). Febuxostat is a more potent inhibitor of XOR than allopurinol, as confirmed by that target UA levels have been achieved more frequently with febuxostat than with allopurinol, particularly in patients with high serum urate concentrations. The pharmacokinetic properties of febuxostat are not dependent on renal clearance, which distinguishes it from allopurinol and may benefit patients with chronic kidney disease. A number of studies are being conducted to further evaluate the cardiovascular safety of febuxostat and its possible positive effects in preserving renal function. Of importance is the fact that febuxostat does not require dose adjustment in elderly patients.https://mrj.ima-press.net/mrj/article/view/844gouthyperuricemiafebuxostatallopurinolchronic kidney diseasescardiovascular diseases |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
M. S. Petrova М. M. Musiychuk V. I. Mazurov |
| spellingShingle |
M. S. Petrova М. M. Musiychuk V. I. Mazurov The current treatment strategy for gouty arthritis Современная ревматология gout hyperuricemia febuxostat allopurinol chronic kidney diseases cardiovascular diseases |
| author_facet |
M. S. Petrova М. M. Musiychuk V. I. Mazurov |
| author_sort |
M. S. Petrova |
| title |
The current treatment strategy for gouty arthritis |
| title_short |
The current treatment strategy for gouty arthritis |
| title_full |
The current treatment strategy for gouty arthritis |
| title_fullStr |
The current treatment strategy for gouty arthritis |
| title_full_unstemmed |
The current treatment strategy for gouty arthritis |
| title_sort |
current treatment strategy for gouty arthritis |
| publisher |
IMA-PRESS LLC |
| series |
Современная ревматология |
| issn |
1996-7012 2310-158X |
| publishDate |
2018-09-01 |
| description |
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA). Febuxostat is a more potent inhibitor of XOR than allopurinol, as confirmed by that target UA levels have been achieved more frequently with febuxostat than with allopurinol, particularly in patients with high serum urate concentrations. The pharmacokinetic properties of febuxostat are not dependent on renal clearance, which distinguishes it from allopurinol and may benefit patients with chronic kidney disease. A number of studies are being conducted to further evaluate the cardiovascular safety of febuxostat and its possible positive effects in preserving renal function. Of importance is the fact that febuxostat does not require dose adjustment in elderly patients. |
| topic |
gout hyperuricemia febuxostat allopurinol chronic kidney diseases cardiovascular diseases |
| url |
https://mrj.ima-press.net/mrj/article/view/844 |
| work_keys_str_mv |
AT mspetrova thecurrenttreatmentstrategyforgoutyarthritis AT mmmusiychuk thecurrenttreatmentstrategyforgoutyarthritis AT vimazurov thecurrenttreatmentstrategyforgoutyarthritis AT mspetrova currenttreatmentstrategyforgoutyarthritis AT mmmusiychuk currenttreatmentstrategyforgoutyarthritis AT vimazurov currenttreatmentstrategyforgoutyarthritis |
| _version_ |
1721250185983557632 |